Arbutus Biopharma Reports Promising Data and Restructuring Plans in Q2 2024
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its second quarter 2024 financial results and provided an update on its corporate strategy.
Arbutus Biopharma Reports Promising Data and Restructuring Plans in Q2 2024 Read More